Showing results (51-60 of 1,827) with videos related to

Sort By:
Pageof 183
ESMO Open|September 12, 2021
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patientsM Del Re, C Omarini, L Diodati, et al.
ESMO Open|September 4, 2025
Explainable machine learning models based on clinical trial surrogate outcomes for predicting overall survival in head and neck cancersW Hwang, H A Jung, L J Worth, et al.
ESMO Open|September 5, 2025
Consensus statement on the multidisciplinary treatment of nasopharyngeal carcinoma with immune checkpoint inhibitors in ChinaG Wang, J Qin, W Nong, et al.
ESMO Open|September 5, 2025
Toxicity and efficacy of antibody-drug conjugates in advanced solid tumors: a retrospective single-center analysis of clinical trialsR Woodford, H Almarzouq, N Beygozlu, et al.
ESMO Open|September 6, 2025
Phase I dose-escalation trial of AMXT 1501 dicaprate plus difluoromethylornithine: a dual-agent approach targeting immunosuppressive polyamine metabolismS A Piha-Paul, A W Tolcher, A L Vandross, et al.
ESMO Open|August 29, 2025
Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients-exploratory results from TITAN-RCCA Fritzsch, K Leucht, N Röber, et al.
ESMO Open|May 23, 2021
The EMA assessment of avapritinib in the treatment of gastrointestinal stromal tumours harbouring the PDGFRA D842V mutationA Trullas-Jimeno, J Delgado, B Garcia-Ochoa, et al.
ESMO Open|May 13, 2021
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapyA Bamias, A S Merseburger, Y Loriot, et al.
ESMO Open|May 13, 2021
Lack of prognostic impact of sentinel node micro-metastases in endocrine receptor-positive early breast cancer: results from a large multicenter cohort☆G Houvenaeghel, A de Nonneville, M Cohen, et al.
ESMO Open|May 13, 2021
A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903K Ito, M Morise, K Wakuda, et al.
Pageof 183